A sharp improvement in margins and fresh 2030 targets have helped the DNA sequencing group recover from a July sales warning, though regional headwinds have not gone away.

Oxford Nanopore Technologies plc (LSE: ONT) has given investors a turbulent ride in 2026. The FTSE 250 life sciences company, which develops portable DNA and RNA sequencing devices, saw its shares slump in July after warning on first-half revenue, only to rally strongly in August when interim results showed that its cost discipline and margin improvements were starting to bite. With the group now in its final quarter of the year, attention is focused on whether it can deliver the stronger second half implied by its guidance.

From sales miss to margin surprise

On 13 July, Oxford Nanopore warned that first-half revenue would come in below management's expectations, citing a roughly 16% fall in sales in China, linked to tighter export controls and changes to its commercial set-up there, together with a 14% decline in the Middle East and the timing of orders in the Americas. The shares fell 11% to 106.5p that day, the steepest decline in the FTSE 250.

The full interim results on 19 August, however, were received far more warmly. Revenue for the six months to 30 June rose 10.5% to £116.7 million, or around 12% at constant currency. Gross margin jumped 400 basis points to 62.2%, while operating costs fell by close to 7%. As a result, the adjusted EBITDA loss more than halved to £22.1 million from £48.3 million, and the net loss narrowed to £48.0 million from £71.8 million. The shares rose 6.8% to around 130.6p on the morning of the results, and commentators noted it was the stock's strongest session in more than seven months.

Clinical and biopharma lead the way

Growth was strongest in the newer end markets the company is targeting. Clinical revenue rose about 35% to £17.6 million and biopharma climbed 25% to £9.5 million. Industrial revenue increased 6.2% to £13.7 million, while the core research market, still by far the largest segment, grew 5.4% to £76 million. Outside China and the Middle East, the company had earlier said constant-currency growth in the first half was 16%.

Alongside the results, management set out new longer-term ambitions for 2030: revenue of more than US$700 million, with growth weighted towards biopharma and clinical customers, and an adjusted EBITDA margin above 15%, with further improvement expected after that. The company said it was tracking well towards adjusted EBITDA breakeven in 2027 and is targeting positive free cash flow in 2028.

Guidance and cash position

For 2026, Oxford Nanopore guided to constant-currency revenue growth of 16% to 20% excluding licensing income, or 23% to 27% including expected collaboration and licensing revenue in the second half. Gross margin is expected at around 62%, rising to about 64% including licensing. Cash, cash equivalents and liquid investments stood at £234.5 million at the end of June, down from £302.8 million at the end of December 2025, which leaves the balance sheet a key area of scrutiny as the company works towards breakeven.

Broker views remain constructive but measured. Berenberg retained a buy rating after the results but trimmed its price target to 200p from 220p, pointing to regional revenue headwinds while describing the company as comfortably on course for breakeven in 2027. The challenge for the remainder of the year is clear: second-half revenue will need to accelerate meaningfully to meet guidance, and the contribution of one-off licensing income will be closely watched.